Ad is loading...
MIEFX
Price
$13.35
Change
-$0.07 (-0.52%)
Updated
Nov 15 closing price
RNWHX
Price
$79.27
Change
-$0.78 (-0.97%)
Updated
Nov 15 closing price
Ad is loading...

MIEFX vs RNWHX

Header iconMIEFX vs RNWHX Comparison
Open Charts MIEFX vs RNWHXBanner chart's image
Matthews Emerging Markets Equity Ins
Price$13.35
Change-$0.07 (-0.52%)
VolumeN/A
CapitalizationN/A
American Funds New World R5E
Price$79.27
Change-$0.78 (-0.97%)
VolumeN/A
CapitalizationN/A
MIEFX vs RNWHX Comparison Chart
Loading...
View a ticker or compare two or three
VS
MIEFX vs. RNWHX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MIEFX is a Hold and RNWHX is a Buy.

FUNDAMENTALS
Fundamentals
RNWHX has more cash in the bank: 60.9B vs. MIEFX (23.3M). MIEFX pays higher dividends than RNWHX: MIEFX (2.00) vs RNWHX (1.44). MIEFX was incepted earlier than RNWHX: MIEFX (5 years) vs RNWHX (9 years). RNWHX is a more actively managed with annual turnover of: 32.00 vs. MIEFX (26.39). RNWHX has a lower initial minimum investment than MIEFX: RNWHX (250) vs MIEFX (100000). MIEFX annual gain was more profitable for investors over the last year : 18.69 vs. RNWHX (11.41).
MIEFXRNWHXMIEFX / RNWHX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence5 years9 years-
Gain YTD12.7537.006182%
Front LoadN/AN/A-
Min. Initial Investment10000025040,000%
Min. Initial Investment IRAN/AN/A-
Net Assets23.3M60.9B0%
Annual Yield % from dividends2.001.44139%
Returns for 1 year18.6911.41164%
Returns for 3 years-13.36-14.8390%
Returns for 5 yearsN/A16.60-
Returns for 10 yearsN/AN/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RDCM11.610.61
+5.55%
Radcom Ltd
CBL27.26-0.03
-0.11%
CBL & Associates Properties
FLEX37.20-0.44
-1.17%
Flex Ltd
CPOP1.19-0.08
-6.30%
Pop Culture Group Co Ltd
DYN28.39-1.92
-6.33%
Dyne Therapeutics